Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.002
Buy
RSI(14)
50.211
Neutral
STOCH(KDJ)(9,3,3)
28.445
Sell
ATR(14)
0.074
High Vlolatility
CCI(14)
-11.766
Neutral
Williams %R
54.826
Neutral
TRIX(12,20)
0.513
Sell
StochRSI(14)
0.000
Sell
Search
Talphera Inc
TLPHAdd to Watchlist
0.848USD
-0.050-5.52%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
41.83MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Talphera Inc
Currency: USD Updated: 2026-05-15Key Insights
Talphera Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 96 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.25.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Talphera Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Talphera Inc Highlights
StrengthsRisks
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.00K.
Undervalued
The company’s latest PE is -2.52, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 20.36M shares, increasing 3.54% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 257.38K shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
3.250
Target Price
+262.12%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Talphera Inc is 5.39, ranking 151 out of 155 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 1.43%.
Score
Financials
5.31
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.07
Operational Efficiency
2.84
Growth Potential
4.66
Shareholder Returns
7.08
Talphera Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Talphera Inc is 6.97, ranking 102 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -2.52, which is -117.96% below the recent high of 0.45 and -53.37% above the recent low of -3.86.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 96/155
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Talphera Inc is 8.00, ranking 58 out of 155 in the Pharmaceuticals industry. The average price target is 3.50, with a high of 6.00 and a low of 3.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
3.250
Target Price
+262.12%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Talphera Inc
TLPH
2
Amgen Inc
AMGN
38
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Talphera Inc is 6.81, ranking 76 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 0.98 and the support level at 0.72, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.874
Sell
MA10
0.882
Sell
MA20
0.843
Buy
MA50
0.817
Buy
MA100
0.892
Sell
MA200
0.932
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Talphera Inc is 3.00, ranking 94 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 40.00%, representing a quarter-over-quarter increase of 0.70%. The largest institutional shareholder is James Simons, holding a total of 237.75K shares, representing 0.46% of shares outstanding, with 676.44% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Talphera Inc is 2.24, ranking 130 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.79. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Talphera Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
0.78
VaR
+8.69%
240-Day Maximum Drawdown
+50.53%
240-Day Volatility
+127.43%
Return
Best Daily Return
60 days
+20.92%
120 days
+20.92%
5 years
+49.13%
Worst Daily Return
60 days
-9.63%
120 days
-13.49%
5 years
-25.61%
Sharpe Ratio
60 days
+0.63
120 days
-0.86
5 years
-0.24
Risk Assessment
Maximum Drawdown
240 days
+50.53%
3 years
+73.37%
5 years
+98.42%
Return-to-Drawdown Ratio
240 days
+1.53
3 years
-0.10
5 years
-0.20
Skewness
240 days
+2.60
3 years
+1.52
5 years
+1.33
Volatility
Realised Volatility
240 days
+127.43%
5 years
+121.73%
Standardised True Range
240 days
+9.36%
5 years
+32.58%
Downside Risk-Adjusted Return
120 days
-141.12%
240 days
-141.12%
Maximum Daily Upside Volatility
60 days
+71.71%
Maximum Daily Downside Volatility
60 days
+55.07%
Liquidity
Average Turnover Rate
60 days
+0.92%
120 days
+1.26%
5 years
--
Turnover Deviation
20 days
-73.64%
60 days
-65.52%
120 days
-52.76%
Peer Comparison
Pharmaceuticals
Talphera Inc
TLPH
5.88 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
9.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
